ijms-logo

Journal Browser

Journal Browser

Advanced Biochemical Research: Transcription in Cancer Initiation and Progression

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Biochemistry".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 9236

Special Issue Editor


E-Mail Website
Guest Editor
Department of General Biophysics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland
Interests: transcription; epigenetics; PARP1; SWI/SNF; EP300; differentiation; cancerogenesis; chromatin; transcription factors; transcription co-factors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The transformation of normal healthy cells into cancer cells is a complex multistep process, mostly associated with the de-differentiation of specialized cells, the re-entrance of G0/G1-arrested cells to mitotic divisions, the ability to spread and invade tissues, as well as immortality. Although the initiation of carcinogenesis is linked with mutations and a loss of genomic stability, the following promotion and progression steps require alteration also in other “-omics”. Transcriptional reprogramming adapts the proteome of the transforming cell to new phenotypes by facilitating a gradual decrease in the expression of cell type or highly specific tissue genes, and by enhancing the expression of factors that promote proliferation, migration, and metastases.

Our issue is dedicated to the elucidation of the essential transcription-relevant events that contribute to carcinogenesis, and to the identification of emerging hubs where gene transcription and malignancy interact with each other. Therefore, we invite submissions that cover genome-wide as well as gene-specific chromatin remodeling that accompanies all stages of tumor development. We aim to identify transcription factors, co-factors, nucleosome readers, writers, and erasers that drive cell transformation. Our Specials Issue also aims to publish papers dealing with the molecular basis of oncogene expression, the repression of tumor suppressors, the role of cell cycle progression, and E2F-dependent gene transcription in gaining the cancer phenotype. Likewise, we are particularly interested in all aspects dealing with transcription of factors, which make malignant cells resistant to anti-cancer approaches.

Dr. Agnieszka Zdzislawa Robaszkiewicz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • transcription
  • transcription factors and co-factors
  • chromatin remodeling
  • epigenetic modification
  • oncogenes
  • suppressors
  • cell cycle
  • E2F-dependent gene transcription
  • tumor resistance
  • signaling

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review, Other

19 pages, 5304 KiB  
Article
NCOA7 Regulates Growth and Metastasis of Clear Cell Renal Cell Carcinoma via MAPK/ERK Signaling Pathway
by Jiayu Guo, Shuai Ke, Qi Chen, Jiangqiao Zhou, Jia Guo and Tao Qiu
Int. J. Mol. Sci. 2023, 24(14), 11584; https://doi.org/10.3390/ijms241411584 - 18 Jul 2023
Cited by 2 | Viewed by 1258
Abstract
NCOA7 is a nuclear receptor coactivator that is downregulated in a variety of cancers. However, the expression and prognostic significance of NCOA7 in clear cell renal cell carcinoma (ccRCC) remain unknown. The expression of NCOA7 in ccRCC tissues was analyzed using bioinformatics analysis, [...] Read more.
NCOA7 is a nuclear receptor coactivator that is downregulated in a variety of cancers. However, the expression and prognostic significance of NCOA7 in clear cell renal cell carcinoma (ccRCC) remain unknown. The expression of NCOA7 in ccRCC tissues was analyzed using bioinformatics analysis, Western blotting, and immunohistochemistry. Kaplan–Meier analysis, the receiver operating characteristic (ROC) curve, and clinicopathological correlation analysis were used to assess the predictive power of NCOA7. Overexpression function tests were conducted in cells and mouse models to clarify the function and mechanism of NCOA7 in inhibiting the progression of ccRCC. NCOA7 expression was downregulated in all three subtypes of renal cell carcinoma, and only had significant prognostic value for patients with ccRCC. NCOA7 overexpression inhibited the proliferation, invasion, and metastasis of ccRCC cells in vivo and in vitro. Mechanistically, NCOA7 inhibited the MAPK/ERK pathway to regulate epithelial–mesenchymal transformation (EMT) and apoptosis, thereby inhibiting the progression of ccRCC. NCOA7 inhibits tumor growth and metastasis of ccRCC through the MAPK/ERK pathway, thus indicating its potential as a prognostic marker and therapeutic target for ccRCC. Full article
Show Figures

Figure 1

Review

Jump to: Research, Other

12 pages, 1558 KiB  
Review
Transcription Factor MYB as Therapeutic Target: Current Developments
by Karl-Heinz Klempnauer
Int. J. Mol. Sci. 2024, 25(6), 3231; https://doi.org/10.3390/ijms25063231 - 12 Mar 2024
Viewed by 763
Abstract
The MYB protein is a pivotal player in the cellular transcriptional network, influencing major important processes such as cell proliferation, differentiation, and apoptosis. Because of its role in oncogenesis, MYB is now a compelling target for therapeutic interventions in cancer research. This review [...] Read more.
The MYB protein is a pivotal player in the cellular transcriptional network, influencing major important processes such as cell proliferation, differentiation, and apoptosis. Because of its role in oncogenesis, MYB is now a compelling target for therapeutic interventions in cancer research. This review summarizes its molecular functions and current therapeutic approaches aiming to inhibit its oncogenic activity. Full article
Show Figures

Figure 1

Other

Jump to: Research, Review

7 pages, 653 KiB  
Opinion
Concern about the Effectiveness of mRNA Vaccination Technology and Its Long-Term Safety: Potential Interference on miRNA Machinery
by Gianmarco Stati, Paolo Amerio, Mario Nubile, Silvia Sancilio, Francesco Rossi and Roberta Di Pietro
Int. J. Mol. Sci. 2023, 24(2), 1404; https://doi.org/10.3390/ijms24021404 - 11 Jan 2023
Cited by 2 | Viewed by 6553
Abstract
After the outbreak of the pandemic due to COVID-19 infection, several vaccines were developed on short timelines to counteract the public health crisis. To allow the administration of mRNA vaccines through a faster-paced approval process, the Emergency Use Authorization (EUA) was applied. The [...] Read more.
After the outbreak of the pandemic due to COVID-19 infection, several vaccines were developed on short timelines to counteract the public health crisis. To allow the administration of mRNA vaccines through a faster-paced approval process, the Emergency Use Authorization (EUA) was applied. The Ba.5 (omicron) variant of SARS-CoV-2 is the predominant one at this moment. Its highly mutable single-stranded RNA genome, along with its high transmissivity, generated concern about the effectiveness of vaccination. The interaction between the vaccine and the host cell is finely regulated by miRNA machinery, a complex network that oversees a wide range of biological processes. The dysregulation of miRNA machinery has been associated with the development of clinical complications during COVID-19 infection and, moreover, to several human pathologies, among which is cancer disease. Now that in some areas, four doses of mRNA vaccine have been administered, it is natural to wonder about its effectiveness and long-term safety. Full article
Show Figures

Figure 1

Back to TopTop